$88.46
3.40% yesterday
NYSE, Nov 25, 10:10 pm CET
ISIN
US4050241003
Symbol
HAE

Haemonetics Corporation Stock price

$88.46
+12.90 17.07% 1M
+0.12 0.14% 6M
+2.95 3.45% YTD
+6.48 7.90% 1Y
+33.15 59.93% 3Y
-31.80 26.44% 5Y
+51.08 136.65% 10Y
NYSE, Closing price Mon, Nov 25 2024
+2.91 3.40%
ISIN
US4050241003
Symbol
HAE
Sector

Key metrics

Market capitalization $4.44b
Enterprise Value $5.37b
P/E (TTM) P/E ratio 36.74
EV/FCF (TTM) EV/FCF 141.72
EV/Sales (TTM) EV/Sales 3.94
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 5.07
Revenue growth (TTM) Revenue growth 9.84%
Revenue (TTM) Revenue $1.36b
EBIT (operating result TTM) EBIT $205.98m
Free Cash Flow (TTM) Free Cash Flow $37.88m
Cash position $299.28m
EPS (TTM) EPS $2.41
P/E forward 27.37
P/S forward 3.19
EV/Sales forward 3.85
Short interest 16.17%
Show more

Is Haemonetics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Haemonetics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Haemonetics Corporation forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Haemonetics Corporation forecast:

Buy
82%
Hold
18%

Financial data from Haemonetics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,361 1,361
10% 10%
100%
- Direct Costs 666 666
9% 9%
49%
695 695
10% 10%
51%
- Selling and Administrative Expenses 322 322
9% 9%
24%
- Research and Development Expense 58 58
10% 10%
4%
316 316
11% 11%
23%
- Depreciation and Amortization 110 110
17% 17%
8%
EBIT (Operating Income) EBIT 206 206
9% 9%
15%
Net Profit 124 124
3% 3%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Haemonetics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Haemonetics Corporation Stock News

Neutral
PRNewsWire
19 days ago
Financial release accessible online BOSTON , Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at...
Neutral
PRNewsWire
about 2 months ago
BOSTON , Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024.
Neutral
PRNewsWire
3 months ago
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® port...
More Haemonetics Corporation News

Company Profile

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Head office United States
CEO Christopher Simon
Employees 3,657
Founded 1971
Website www.haemonetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today